Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jun 22;12(7):1089.
doi: 10.3390/antibiotics12071089.

Bacteriophage-Antibiotic Combination Therapy against Pseudomonas aeruginosa

Guillermo Santamaría-Corral  1 , Abrar Senhaji-Kacha  1   2 , Antonio Broncano-Lavado  1 , Jaime Esteban  1   2 , Meritxell García-Quintanilla  1   2
Affiliations
Review

Bacteriophage-Antibiotic Combination Therapy against Pseudomonas aeruginosa

Guillermo Santamaría-Corral et al. Antibiotics (Basel). .

Abstract

Phage therapy is an alternative therapy that is being used as the last resource against infections caused by multidrug-resistant bacteria after the failure of standard treatments. Pseudomonas aeruginosa can cause pneumonia, septicemia, urinary tract, and surgery site infections mainly in immunocompromised people, although it can cause infections in many different patient profiles. Cystic fibrosis patients are particularly vulnerable. In vitro and in vivo studies of phage therapy against P. aeruginosa include both bacteriophages alone and combined with antibiotics. However, the former is the most promising strategy utilized in clinical infections. This review summarizes the recent studies of phage-antibiotic combinations, highlighting the synergistic effects of in vitro and in vivo experiments and successful treatments in patients.

Keywords: Pseudomonas aeruginosa; bacteriophage; combination; treatment.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Riquelme S.A., Liimatta K., Wong Fok Lung T., Fields B., Ahn D., Chen D., Lozano C., Sáenz Y., Uhlemann A.C., Kahl B.C., et al. Pseudomonas aeruginosa Utilizes Host-Derived Itaconate to Redirect Its Metabolism to Promote Biofilm Formation. Cell Metab. 2020;31:1091–1106.e6. doi: 10.1016/j.cmet.2020.04.017. - DOI - PMC - PubMed
    1. Fernández-Barat L., Ferrer M., De Rosa F., Gabarrús A., Esperatti M., Terraneo S., Rinaudo M., Li Bassi G., Torres A. Intensive care unit-acquired pneumonia due to Pseudomonas aeruginosa with and without multidrug resistance. J. Infect. 2017;74:142–152. doi: 10.1016/j.jinf.2016.11.008. - DOI - PubMed
    1. Jurado-Martín I., Sainz-Mejías M., McClean S. Pseudomonas aeruginosa: An Audacious Pathogen with an Adaptable Arsenal of Virulence Factors. Int. J. Mol. Sci. 2021;22:3128. doi: 10.3390/ijms22063128. - DOI - PMC - PubMed
    1. Reynolds D., Kollef M. The Epidemiology and Pathogenesis and Treatment of Pseudomonas aeruginosa Infections: An Update. Drugs. 2021;81:2117–2131. doi: 10.1007/s40265-021-01635-6. - DOI - PMC - PubMed
    1. Ho J., Tambyah P.A., Paterson D.L. Multiresistant Gram-negative infections: A global perspective. Curr. Opin. Infect. Dis. 2010;23:546–553. doi: 10.1097/QCO.0b013e32833f0d3e. - DOI - PubMed

LinkOut - more resources